Literature DB >> 27148592

Allosteric Modulation of G Protein-Coupled Receptors: An Emerging Approach of Drug Discovery.

Christopher Wild1, Kathryn A Cunningham1, Jia Zhou1.   

Abstract

Allosteric modulation of G protein-coupled receptors (GPCRs) confers several significant advantages over the traditional targeting of orthosteric sites. While the field of allosteric modulation of GPCRs as we now know it will benefit from continued investigation, the explosion of interest has led to a more in-depth understanding as to precisely how allosteric modulators may usher in a new paradigm for drug discovery.

Entities:  

Year:  2014        PMID: 27148592      PMCID: PMC4852709     

Source DB:  PubMed          Journal:  Austin J Pharmacol Ther        ISSN: 2373-6208


  18 in total

1.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors:  Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2012-01-06       Impact factor: 7.446

Review 2.  G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms.

Authors:  Thomas M Bridges; Craig W Lindsley
Journal:  ACS Chem Biol       Date:  2008-07-25       Impact factor: 5.100

Review 3.  Emerging paradigms in GPCR allostery: implications for drug discovery.

Authors:  Denise Wootten; Arthur Christopoulos; Patrick M Sexton
Journal:  Nat Rev Drug Discov       Date:  2013-08       Impact factor: 84.694

Review 4.  '7TM receptor allostery: putting numbers to shapeshifting proteins.

Authors:  Terry P Kenakin
Journal:  Trends Pharmacol Sci       Date:  2009-09-02       Impact factor: 14.819

Review 5.  Lessons from 60 years of pharmaceutical innovation.

Authors:  Bernard Munos
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

Review 6.  Allosteric modulators of the extracellular calcium receptor.

Authors:  E F Nemeth
Journal:  Drug Discov Today Technol       Date:  2013

Review 7.  The 7 TM G-protein-coupled receptor target family.

Authors:  Edgar Jacoby; Rochdi Bouhelal; Marc Gerspacher; Klaus Seuwen
Journal:  ChemMedChem       Date:  2006-08       Impact factor: 3.466

Review 8.  Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.

Authors:  Frank S Menniti; Craig W Lindsley; P Jeffrey Conn; Jayvardhan Pandit; Panayiotis Zagouras; Robert A Volkmann
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

Review 9.  Calcium sensing receptor activators: calcimimetics.

Authors:  Paul E Harrington; Christopher Fotsch
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

Review 10.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.

Authors:  P Jeffrey Conn; Arthur Christopoulos; Craig W Lindsley
Journal:  Nat Rev Drug Discov       Date:  2009-01       Impact factor: 84.694

View more
  6 in total

1.  Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT2C Receptor.

Authors:  Christopher T Wild; Joanna M Miszkiel; Eric A Wold; Claudia A Soto; Chunyong Ding; Rachel M Hartley; Mark A White; Noelle C Anastasio; Kathryn A Cunningham; Jia Zhou
Journal:  J Med Chem       Date:  2018-04-13       Impact factor: 7.446

Review 2.  Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.

Authors:  Leepakshi Khurana; Ken Mackie; Daniele Piomelli; Debra A Kendall
Journal:  Neuropharmacology       Date:  2017-05-17       Impact factor: 5.250

Review 3.  Multi-Target Effects of ß-Caryophyllene and Carnosic Acid at the Crossroads of Mitochondrial Dysfunction and Neurodegeneration: From Oxidative Stress to Microglia-Mediated Neuroinflammation.

Authors:  Roberto Iorio; Giuseppe Celenza; Sabrina Petricca
Journal:  Antioxidants (Basel)       Date:  2022-06-18

Review 4.  Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts.

Authors:  Eric A Wold; Jianping Chen; Kathryn A Cunningham; Jia Zhou
Journal:  J Med Chem       Date:  2018-08-28       Impact factor: 7.446

5.  2-(Fluoromethoxy)-4'-(S-methanesulfonimidoyl)-1,1'-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1 Receptor for Parkinson's Disease.

Authors:  Javier García-Cárceles; Henar Vázquez-Villa; José Brea; David Ladron de Guevara-Miranda; Giovanni Cincilla; Melchor Sánchez-Martínez; Anabel Sánchez-Merino; Sergio Algar; María Teresa de Los Frailes; Richard S Roberts; Juan A Ballesteros; Fernando Rodríguez de Fonseca; Bellinda Benhamú; María I Loza; María L López-Rodríguez
Journal:  J Med Chem       Date:  2022-08-31       Impact factor: 8.039

6.  Computational Analysis of Crystallization Additives for the Identification of New Allosteric Sites.

Authors:  Jade Fogha; Julien Diharce; Alan Obled; Samia Aci-Sèche; Pascal Bonnet
Journal:  ACS Omega       Date:  2020-02-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.